Figure 4—figure supplement 3. | Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice

Open accessCopyright infoDownload PDFDownload figures

Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice

Figure 4—figure supplement 3.

Affiliation details

University of Washington, United States; Fred Hutchinson Cancer Research Center, United States; University of Missouri, United States
Figure 4—figure supplement 3.
Download figureOpen in new tabFigure 4—figure supplement 3. Inclusion of non-age-related deaths does not alter survival outcomes.

(A, B). Survival plots of (A) male and (B) sex-pooled mice fed 126 ppm eudragit or eRapa for 90 days including deaths during the treatment period from non-age-related causes.(A) N=38 vehicle injected, N=38 eRapa. (B) N=20 eudragit males, N=20 126 ppm eRapa males.

DOI: http://dx.doi.org/10.7554/eLife.16351.020